NASDAQ:RLYB - Nasdaq - US75120L1008 - Common Stock - Currency: USD
0.25
0 (-0.71%)
The current stock price of RLYB is 0.25 USD. In the past month the price decreased by -64.29%. In the past year, price decreased by -85.8%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.09 | 306.02B | ||
AMGN | AMGEN INC | 13.99 | 149.08B | ||
GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
ARGX | ARGENX SE - ADR | 318.82 | 36.40B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.89B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
NTRA | NATERA INC | N/A | 20.02B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
BIIB | BIOGEN INC | 7.2 | 17.36B |
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT US
CEO: Martin W. Mackay
Employees: 25
Company Website: https://rallybio.com/
Investor Relations: https://investors.rallybio.com/
Phone: 12038593820
The current stock price of RLYB is 0.25 USD. The price decreased by -0.71% in the last trading session.
The exchange symbol of RALLYBIO CORP is RLYB and it is listed on the Nasdaq exchange.
RLYB stock is listed on the Nasdaq exchange.
11 analysts have analysed RLYB and the average price target is 8.41 USD. This implies a price increase of 3266% is expected in the next year compared to the current price of 0.25. Check the RALLYBIO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
RALLYBIO CORP (RLYB) has a market capitalization of 10.40M USD. This makes RLYB a Nano Cap stock.
RALLYBIO CORP (RLYB) currently has 25 employees.
The Revenue of RALLYBIO CORP (RLYB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the RLYB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RLYB does not pay a dividend.
RALLYBIO CORP (RLYB) will report earnings on 2025-05-13, before the market open.
RALLYBIO CORP (RLYB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.35).
The outstanding short interest for RALLYBIO CORP (RLYB) is 0.92% of its float. Check the ownership tab for more information on the RLYB short interest.
ChartMill assigns a fundamental rating of 3 / 10 to RLYB. No worries on liquidiy or solvency for RLYB as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -1.35. The EPS increased by 26.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -84.83% | ||
ROE | -93.71% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to RLYB. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 18.06% and a revenue growth -100% for RLYB